Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
46.05
USD
+1.32%
+5.28%
+29.32%
Aastrom Biosciences : Vericel to Host Second-Quarter 2015 Earnings Webcast and Conference Call on August 12, 2015
August 11, 2015 at 10:29 am EDT
What:
Vericel Corporation Second-Quarter 2015 Earnings Call
When:
Wednesday, August 12, 2015 at 8:00am (ET)
Where:
http://investors.vcel.com/events.cfm
How:
The conference call will be available live in the Investors section of the Vericel
website at http://investors.vcel.com/events.cfm . Please access the site at least 15
minutes prior to the scheduled start time in order to download the required audio
software if necessary.
To participate in the live call by telephone, please call (877) 312-5881 and
reference Vericel Corporation second-quarter 2015 investor conference call. If
calling from outside the U.S., please use the international phone number (253)
237-1173.
distributed by
Vericel Insider Sold Shares Worth $1,593,550, According to a Recent SEC Filing
Apr. 19
MT
Vericel Insider Sold Shares Worth $1,552,075, According to a Recent SEC Filing
Mar. 15
MT
Vericel Insider Sold Shares Worth $352,047, According to a Recent SEC Filing
Mar. 13
MT
Vericel Insider Sold Shares Worth $367,853, According to a Recent SEC Filing
Mar. 11
MT
Truist Securities Raises Vericel's Price Target to $54 From $51, Keeps Buy Rating
Mar. 01
MT
HC Wainwright Adjusts Price Target on Vericel to $53 From $46, Keeps Buy Rating
Mar. 01
MT
Vericel Q4 EPS, Revenue Increase; Issues 2024 Outlook -- Shares Rise Pre-Bell
Feb. 29
MT
Vericel Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 29
CI
Transcript : Vericel Corporation, Q4 2023 Earnings Call, Feb 29, 2024
Feb. 29
Vericel Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 29
CI
Vericel Corporation Provides Earnings Guidance for the Fiscal Year 2024
Feb. 29
CI
Earnings Flash (VCEL) VERICEL CORPORATION Reports Q4 Revenue $65M, vs. Street Est of $64M
Feb. 29
MT
North American Morning Briefing : Fed's Preferred -2-
Feb. 29
DJ
Vericel Insider Sold Shares Worth $1,677,200, According to a Recent SEC Filing
Feb. 16
MT
North American Morning Briefing : Intel Drags Down -2-
Jan. 26
DJ
Vericel Insider Sold Shares Worth $334,775, According to a Recent SEC Filing
Jan. 24
MT
Vericel Insider Sold Shares Worth $1,280,375, According to a Recent SEC Filing
Jan. 19
MT
Vericel Corporation Provides Earnings Guidance for the Year 2024
Jan. 10
CI
Transcript : Vericel Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM
Jan. 10
Vericel Reports Q4 Preliminary Unaudited Revenue; Shares Rise
Jan. 09
MT
Vericel Corporation Provides Earnings Guidance for the Fourth Quarter and Full-Year 2023
Jan. 09
CI
Vericel Corporation(NasdaqGM:VCEL) added to NASDAQ Biotechnology Index
Dec. 18
CI
Vericel Insider Sold Shares Worth $853,800, According to a Recent SEC Filing
Dec. 15
MT
Vericel Insider Sold Shares Worth $832,909, According to a Recent SEC Filing
Dec. 08
MT
Vericel Insider Sold Shares Worth $617,798, According to a Recent SEC Filing
Dec. 01
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
More about the company
Last Close Price
46.05
USD
Average target price
53.9
USD
Spread / Average Target
+17.05%
Consensus
1st Jan change
Capi.
+29.32% 2.19B -4.66% 87.53B +1.32% 40.42B -19.27% 29.48B +57.86% 25.43B -17.69% 11.49B -43.00% 11.3B -9.14% 11.1B +5.24% 8.75B -8.42% 7.99B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1